Qurient Co Assets per Share

What does Qurient Co do? Qurient Co., Ltd. develops novel therapeutics with two main program phases. The development phase includes Q203 for drug-resistant tuberculosis, Q301 for atopic dermatitis, and Q701 for drug-resistant cancer and anti-cancer immunotherapy. The research phase focuses on five lipoxygenase (5LO) inhibitor asthma medicines and a cyclin dependent kinase 7 (CDK7) inhibitor cancer drug. The company generates revenue through these therapeutic programs, targeting pharmaceutical companies and healthcare providers seeking innovative treatments for resistant diseases and chronic conditions. Qurient's products are developed for specific medical needs, with Q203 addressing tuberculosis that resists standard drugs, Q301 treating skin inflammation conditions, and Q701 enhancing cancer immunotherapy. The research phase programs aim to advance asthma and cancer treatments through novel inhibitors. Pharmaceutical companies and healthcare providers purchase these therapies to address unmet medical needs in their markets. The company's revenue streams come from the development and potential commercialization of Q203, Q301, Q701, and the research phase programs. These programs target segments including tuberculosis treatment, dermatology, oncology, and respiratory diseases. Pharmaceutical firms and healthcare institutions are the primary buyers of Qurient's therapeutic solutions for drug-resistant conditions and advanced treatment options. Qurient Co is one of the most popular companies on Eulerpool.